Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

NCT02416999 is registered in ClinicalTrials.gov with Hebei Yanda Hospital as lead sponsor.

NCT NCT02416999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02416999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas
Lead sponsor
Hebei Yanda Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
May 31, 2015
Completion date
May 31, 2018
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent high-grade glioma